Seoul National University College of Medicine Department of Biochemistry and Korea Advanced Institute of Science and Technology (KAIST) Department of Bio and Brain Engineering joint research team created a’Drug-screening Platform’ for the first time in the world through fusion of brain organoid models derived from Alzheimer’s patients and system biology. Developed.
Alzheimer’s disease is a representative dementia disease that accounts for about 70% of dementia. Until now, the cause of the outbreak is unclear and it is one of the diseases that humanity has not overcome without a fundamental cure.
One of the challenges in developing a treatment for Alzheimer’s disease is that the brains of real living patients cannot be directly used as experimental samples. As a result, it was difficult to accurately evaluate the drug efficacy of the candidate treatment groups.
In order to overcome the obstacles in the development of these treatments, this study built an environment similar to that of a real patient’s brain.
Based on brain organoids derived from real dementia patients, a platform for predicting drug efficacy was developed by fusion of mathematical modeling of biological mechanisms. Brain organoid refers to a 3D artificial mini-brain derived from the patient’s dedifferentiated stem cells (iPSCs). Dedifferentiated stem cells are stem cells that have the property (pluripotency) to differentiate into all types of cells like embryonic stem cells. Through this, the research team overcame experimental limitations by establishing an environment similar to that of a real patient’s brain.
In addition, a network specific to neurons in Alzheimer’s disease was built using a system biology-based mathematical modeling technique. Systems biology is a research paradigm that identifies and explains life phenomena by fusion of IT’s mathematical modeling, computer simulation, and BT’s molecular cell biology experiments.
The research team verified the effectiveness of the neuronal computer model using brain organoids derived from actual Alzheimer’s disease patients and normal groups. This is the first case in the world that verified a system biology-based neuronal computer model as a brain organoid derived from a patient with Alzheimer’s disease.
The brain disease field has been regarded as a wasteland for precision medicine, but the research team believes that this study will help to discover the optimal drug target according to the genotype of Alzheimer’s disease patients.
Prof. In-hee Moo said, “If the optimal drug discovery is made according to the genotype of Alzheimer’s disease patients through the system biology platform, we expect that Korea will be able to preempt the national edge in the development of dementia treatment.
This research was conducted as a national dementia combat technology development project supported by the Ministry of Health and Welfare and the Korea Institute for Health Industry Promotion, and was published on the 12th in the international academic journal’Nature Communications’.
Reporter Moon Se-young email@example.com
Copyrightⓒ’Honest Knowledge for Health’ Comedy.com (http://kormedi.com) / Unauthorized reproduction-redistribution prohibited
*The article has been translated based on the content of 코메디닷컴 by kormedi.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!